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khileshvikram@gmAbstract Lamivudine has been widely used in the treatment of HIV disease. A reliable, sensitive
reversed phase high performance liquid chromatography (RP-HPLC) method was developed and
validated for lamivudine in rabbit plasma. The method was developed on Hypersil BDS C-18
column (250 mm 4.6 mm, 5 mm) using a mobile phase of 0.25% Triethylamine buffer (pH 3.0):
acetonitrile (70:30, v/v). The efﬁcient was monitored by UV detector at 256 nm. The total run time
was 15 min with a ﬂow rate of 1.0 mL/min. Calibration curve was linear over the concentration
range of 25–2000 ng/mL. The retention times of lamivudine and internal standard (Nelﬁnavir) were
8.78 min and 10.86 min, respectively. The developed RP-HPLC method can be successfully applied
for the quantitative pharmacokinetic parameters determination of lamivudine in rabbit model.
& 2011 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Beside global commitment to eradicate the HIV/AIDS, this
disease has spread signiﬁcantly in recent years. Nearly 3.0 million
deaths have occurred due to this pandemic disease each year. In
recent years a new ART (antiretroviral) therapy has beenersity. Production and hosting
n Jiaotong University.
sevier
ail.com (A.V. Singh).developed, which includes single or combination therapy by
antiviral drug. Lamivudine is an analogue of cytidine. It inhibits
both types (I and II) of HIV reverse transcriptase and also the
reverse transcriptase of hepatitis B. It is phosphorylated to active
metabolites that compete for incorporation into viral DNA.
They inhibit the HIV reverse transcriptase enzyme competitively
and act as a chain terminator of DNA synthesis. The lack of a
30-OH group in the incorporated nucleoside analogue prevents
the formation of the 50–30 phosphodiester linkage essential for
DNA chain elongation, and therefore, the viral DNA growth is
terminated [1]. Few methods have been developed for lamivudine
determination by RP-HPLC in human plasma [2–6]. Reviewing
the literature revealed that neither RP-HPLC nor any other
chromatographic method reported for the determination of this
drug in rabbit plasma [7].
This paper describes the development and validation of a
RP-HPLC assay, using UV detector for the quantitative
determination of lamivudine in rabbit plasma.
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Lamivudine was the generous gift from Ranbaxy Pharmaceu-
ticals Limited, Paonta Sahib, India. LamivirTM (Cipla, India)
was purchased from local market. HPLC grade acetonitrile
was procured from Qualigens, India. Potassium dihydrogen
phosphate (KH2PO4) and ortho-phosphoric acid were pur-
chased from Loba Chemie, Mumbai, India. All other chemi-
cals and solvents used were of analytical grade. Water used in
the HPLC analysis was prepared by the water puriﬁer
(Ariums, 611UF, Sartorius, Germany). The mobile phase
and all the solutions were ﬁltered through a 0.45 mm Ultipors
N66s membrane ﬁlter (Pall Life Sciences, USA) prior to use.
2.1. Instrument and software
HPLC system (Waters, USA) consisting of quaternary pump
(WaterTM600), 7725i rheodyne manual injector and UV–Vis
detector of module 2998 and empower-II software were used
for analysis. The plasma samples were processed by using of
Micropipettes (Ependruff, USA), Spinix Vortexer (M37610-
33, Barnstead international, USA), Biofuge Fresco Centrifuge
(Heraeus, Germany), Ultra-Sonicator (Loba Chem, Mumbai),
Nitrogen gas evaporator and Multi-Pulse Vortexer (Glas-
COL, USA).
2.2. Preparation of stock solution of lamivudine
An accurately weighed 10 mg of lamivudine was dissolved in
10 mL of methanol and transferred into a 50 mL volumetric
ﬂask. The stock solution (1000 mg/mL) was stored in a
refrigerator (2–4 1C). From the stock solution working solu-
tions were prepared by serial dilution.
2.3. Preparation of internal standard (IS) stock solution
An accurately weighed nelﬁnavir (10 mg) was dissolved in
10 mL of methanol to obtain 1000 mg/mL of stock solution.
The stock solution was diluted with methanol to obtain a
solution of 50 mg/mL of nelﬁnavir.
2.4. Extraction efﬁciency
The recovery of an analyte is the extraction efﬁciency of an
analytical process, reported as a percentage of the known
amount of an analyte carried through the sample extraction
and processing steps of the method. Different organic extrac-
tion solvents (ethyl acetate, dichloromethane, acetonitrile,
methyl alcohol, hexane and chloroform) were tried in the
experiment, and acetonitrile was proved to be the most
efﬁcient in extracting lamivudine from rabbit plasma and
had a small variation in extraction recoveries over the
concentration range. Spiked plasma sample was prepared in
triplicate at single concentration of 400 ng/mL of lamivudine
and 50 mg/mL of IS, and assayed as described above. The
extraction efﬁciency of lamivudine was determined by com-
paring the peak areas measured after analysis of spiked
plasma sample with those found after direct injection of
non-biological (unextracted) samples into the chromato-
graphic system at the same concentration levels.2.5. Preparation of plasma samples
Plasma samples for calibration and quality control analysis
were prepared by mixing of 100 mL of sample and 10 mL of IS
solution (50 mg/mL). The mixture was vortexed (Glas-COL,
USA) for 10 s and then 1.5 mL of CAN was added and ﬁnally
the samples were extracted for 10 min in a spinx vortexer
(M37610-33, Barnstead international, USA). The plasma
samples were then centrifuged (Biofuge Fresco Centrifuge,
Heraeus, Germany) at 10,000 rpm for 5 min at 4 1C and ﬁnally
organic solvent was evaporated under nitrogen atmosphere.
The samples were then reconstituted by addition of 100 mL of
diluents. The samples were then vortexed using multi-pulse
vortexer and ﬁnally 20 mL sample volume was injected into
HPLC system for analysis.
2.6. Preparation of calibration curve
Standards were prepared in fresh medium by spiking 20 mL
each of the working solution of lamivudine into the control
blank plasma (180 mL) to give the concentration range (25.86,
50.77, 101.53, 203.06, 406.12, 846.09, 1244.24, 1637.16 and
2046.45 ng/mL).
2.7. Validation of methods
The validation of an analytical method conﬁrms the char-
acteristics of the method to satisfy the requirements of the
application. The method was validated following ICH guide-
lines for speciﬁcity, recovery, linearity, precision and stability.
Under he validation study the following parameters were
studied:
2.7.1. Speciﬁcity
The speciﬁcity criterion demonstrates that the results of the
method are not affected by the presence of interference, i.e.
whether the compound of interest elutes without interfering
with other compounds and components of plasma. The
speciﬁcity of the method was determined by comparing the
chromatograms obtained from the aqueous samples of lami-
vudine and IS with those obtained from blank plasma. Blank
plasma samples from each of three rabbits were processed in
presence of IS. The solutions each containing 404.16 ng/mL
were injected into the column under the optimized chromato-
graphic conditions to obtain the chromatographic peaks of
lamivudine in plasma in presence of IS.
2.7.2. Linearity
Quantitative analytical results are highly inﬂuenced by the
quality of the calibration curve. Nine different concentrations
of lamivudine with ﬁxed concentration of IS in blank plasma
were processed and calibration curve was constructed in the
speciﬁc concentration range. The calibration curve was plotted
between the ratio of peak areas of lamivudine to IS and
concentration of lamivudine.
2.7.3. Precision and accuracy
Both repeatability (within a day precision) and reproducibility
(between days precision) were determined. Three quality
control samples were subjected for the study. Five injections
of each of the speciﬁed quality control samples at three levels
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ability, and over a period of 5 days for reproducibility. Mean
and relative standard deviations were calculated and used to
predict the accuracy and precision of the method.2.7.4. Stability
The quality control standards containing 204.16, 402.23 and
801.69 ng/mL of lamivudine were subjected for detection of
stability of the drug in plasma. One set of six samples each was
kept in poly propylene tube and subjected to freeze-thaw
cycles each at 20 1C and for 24 h. The second sets of six
samples each was kept at room temperature for 24 h and the
third set of six samples each was kept at room temperature for
1 month. All the samples were analyzed by standard chroma-
tographic conditioned to determine their peak areas. Samples
were considered to be stable when the ﬁnal assay values of
samples were found similar to that of the initial assay value of
the drug.2.8. Pharmacokinetic study in rabbits
The method described above was applied to quantify the
plasma concentration of lamivudine in a single-dose pharma-
cokinetic study conducted on three white male albino rabbits.
The protocol was approved by the Institutional Ethical
Committee at the Gayatri College of Pharmacy, Orissa, India.
The experiments were conducted as per CPCSEA (Committee
for Prevention, Control and Supervision of Experimental
Animals) guidelines. The rabbits weighing 1.5–2.5 kg were
housed with free access to food and water, except for the ﬁnal
12 h before experimentation. After a single oral administration
of 100 mg of lamivudine (LamivirTM), 2.0 mL of blood
samples were collected from the marginal ear vein at 0, 0.5,
1, 2, 4, 6, 8, 12 and 24 h time-points into heparinized collection
tubes. The blood was immediately centrifuged (1000 g) for
10 min at an ambient temperature. The supernatant plasma
layer was separated and stored at 20 1C until analyzed. The
plasma samples were analyzed for lamivudine concentrations
as described above. The total area under the observed plasmaFigure 1 Chromatogram of the mixture of lamconcentration–time curve (AUC) was calculated using the
linear trapezoidal rule. The ﬁrst order elimination rate con-
stant (Kel) was estimated by the least square regression of
the points describing the terminal log–linear decaying phase.
T1/2 was derived from Kel (T1/2¼ ln 2/Kel). The absorption rate
constant (Ka) was determined by residual method. The max-
imum observed lamivudine concentration (Cmax) and the time
at which Cmax was observed (Tmax) were reported directly
from the proﬁle.3. Result and discussion
Normal phase chromatography can be used for the separation
of non-ionic and non-polar substances, while reversed phase
chromatography (C8 and C18 column) can be used for the
separation of non-ionic, ionic non-polar and semi polar
substances. Octadecylsilane (C18 column) reversed phase
column was selected for lamivudine. A mixture of 0.25%
Triethylamine buffer (pH 3.0) and acetonitrile was used as
mobile phase for the analysis of lamivudine. The optimum
ratio of buffer and acetonitrile used in the current investiga-
tion was 70:30 (v/v), which was selected on the basis of
resolution and absence of interference. The best resolution and
sensitivity of the method was obtained at 256 nm with 1 mL/min
ﬂow rate of the mobile phase.
3.1. Speciﬁcity
Typical chromatogram (Fig. 1) of mixture of lamivudine and
IS revealed that they are well separated under HPLC condi-
tion applied. A chromatogram of blank plasma sample is
shown in Fig. 2. The retention time was found to be 8.787 min
for lamivudine and 10.864 min for IS. Fig. 3, which is the
overlapping of the chromatogram of lamivudine (Fig. 1) with
the chromatogram of blank plasma (Fig. 2), indicated absence
of interference of plasma components around the zone of
retention time of lamivudine analysis. The chromatograph
of medium level quality control sample i.e. 408.19 ng/mL of
lamivudine (Fig. 4) showed a good resolution peaks forivudine and nelﬁnavir (IS) in mobile phase.
Figure 2 Chromatogram of blank plasma of rabbit.
Figure 3 Overlapping of chromatograms of lamivudine–IS mixture with blank plasma.
Figure 4 Chromatogram of medium level quality control sample of lamivudine.
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Table 2 Linear regression data for the calibration curve
(n¼6), concentration of lamivudine versus peak area ratio
of lamivudine:IS.
Parameter Values
Absorption maxima (nm) 256
Linearity range (ng/mL) 25–2000
Linear regression equation Y¼0.0011Xþ0.0104
Correlation coefﬁcient 0.9987
Slope 0.0011
Intercept 0.0104
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of plasma components.
3.2. Selection of extraction solvents
The solvent which was capable of extracting maximum
amount of drug from plasma sample was selected for proces-
sing of the samples. The recovery of drug was found to be
83.52%72.1, 76.46%71.7, 71.08%72.2, 62.88%71.1 and
59.04%70.8 (w/w) in acetonitrile, hexane, chloroform,
dichloromethane and methanol respectively at all three con-
centration levels, which conﬁrm the extraction efﬁciency of the
solvents. Among the solvents, acetonitrile showed maximum
amount of drug recovered. Hence, acetonitrile was selected as
the extracting solvent. The recovery of IS was also found to be
maximum in acetonitrile which was 91.19%72.2 (w/w).
3.3. Linearity range
The ratio of peak area of lamivudine to IS at various
concentrations of lamivudine in plasma is shown in Table 1.
A calibration curve was plotted between peak area ratios of
lamivudine to IS versus lamivudine concentration in plasma,
which is presented in Fig. 5. The chromatographic responses
(ratio of peak area of lamivudine to IS versus lamivudine
concentration) were found to be linear over an analytical
range of 25.38–2046.45 ng/mL with regression coefﬁcientTable 1 Peak area of the chromatogram of lamivudine
and IS at different concentration of lamivudine.
Concentration
of lamivudine
(ng/mL)
Peak area of the chromatogram Ratio of
peak
areaLamivudine IS (Nelﬁnavir)
25.38 8825 350,425 0.0252
50.77 16,178 362,761 0.0446
101.53 40,620 366,808 0.1107
203.06 75,781 329,747 0.2298
406.12 158,161 331,290 0.4774
846.09 348,025 378,573 0.9193
1244.24 483,753 370,746 1.3048
1637.16 666,091 370,086 1.7998
2046.45 800,643 372,877 2.1472
Figure 5 Standard calibration curve of lamivudine in rabbit
plasma.value of 0.998, which showed reproducibility. The regression
equation value of the calibration curve is presented in Table 2.
3.4. Precision and accuracy
The accuracy of the measurements was determined by using
three quality control samples and the results are presented in
Table 3. The relative standard deviation (RSD) of intra-day
assay of the drug was ranged from 3.3 to 8.4% and for the
inter-day assay was from 4.7 to 10.3%. Accurate data ranged
from 98.52 to 99.97% for both the conditions indicated that
there was no interference from endogenous plasma compo-
nents. Inter-day as well as intra-day replicates of lamivudine
resulted a RSD value less than 10.3% (should be less than
15% according to CDER guidance for bioanalytical method
validation), which revealed that the precision of the proposed
method is very high.
3.5. Stability
The result of the stability validation is presented in Table 4.
The results revealed that the ﬁnal concentration of the drug in
each quality control samples at stability conditions i.e. freeze–
thaw condition, 24 h storage and one month storage was
found to be similar with initial concentration. The RSD value
(n¼6) of ﬁnal concentration of drug after storing the samples
in all the stability conditions was found to be less than 15%.
The accuracy of stored samples was found to be nearly
equivalent to 100%. Hence, it can be inferred that lamivudine
was stable in rabbit plasma.
3.6. Pharmacokinetic study in rabbits
The developed method was applied to quantify lamivudine
concentration in pharmacokinetic study carried out on rab-
bits. The mean plasma concentration versus time proﬁle
following a single oral administration of lamivudine to three
rabbits is presented in Fig. 6. Various other pharmacokinetic
parameters have been summarized in Table 5.4. Conclusion
A novel, simple and sensitive RP-HPLC method has been
developed and validated for the estimation of lamivudine in
rabbit plasma using UV-detector. A good resolution was
obtained between lamivudine and IS with retention time of
Table 3 Precision and accuracy of method for the estimation of lamivudine in rabbit plasma.
Concentration (ng/mL) Intra-day precision Inter-day precision
Mean (ng/mL) RSD (%) Accuracy (%) Mean (ng/mL) RSD (%) Accuracy (%)
101.530 101.50 3.3 99.97 100.03 5.6 98.52
406.121 404.15 4.9 99.51 400.54 4.7 98.62
1244.44 1243.22 8.4 99.90 1241.343 10.3 99.75
Table 4 Stability of lamivudine in rabbit plasma.
Stability (n¼6) Concentration (ng/mL) of
lamivudine in quality control
samples
101.530 406.121 1244.244
Freeze thaw stability
Initial (mean, (ng/mL)) 99.23 402.54 1241.343
Final (mean, (ng/mL)) 99.01 405.85 1245.693
Deviation (%) 0.22 0.82 0.35
RSD (%) 7.4 8.9 10.3
Accuracy (%) 99.77 100.82 100.35
24 h stability
Initial (mean, (ng/mL)) 102.34 402.76 1243.98
Final (mean, (ng/mL)) 101.54 403.56 1246.33
Deviation (%) 0.78 0.20 0.19
RSD (%) 11.1 6.8 5.9
Accuracy (%) 99.21 100.19 100.18
1 month stability
Initial (mean, (ng/mL)) 100.04 407.74 1245.23
Final (mean, (ng/mL)) 103.31 403.65 1248.89
Deviation (%) 3.26 1.00 0.29
RSD (%) 9.2 8.9 10.1
Accuracy (%) 103.26 98.99 100.29
Figure 6 Mean plasma concentration versus time proﬁle follow-
ing a single oral administration of lamivudine (100 mg) to rabbits
(n¼3).
Table 5 Pharmacokinetic parameters of NTG after a
single oral dose of 100 mg lamivudine to rabbits (n¼3).
Pharmacokinetic parameters Obseerved
value
Maximum plasma concentration,
Cmax (ng/mL)
12,784.913
Time required to reach maximum plasma
concentration, Tmax (h)
1.00
Area under curve at 24 h, AUC (0-N)
(ng h/mL)
54,206.284
Area under momentum curve at 24 h,
AUMC (0-N) (ng h2/mL)
227,067.968
Volume of distribution, Vd (L) 9.574
Plasma half life (T1/2) (h) 3.594
Absorption rate constant, Ka (h
1) 2.142
Elimination rate constant, Kel (h
1) 0.193
Mean residence time, MRT (h) 4.189
Clearance, Cl (L/h) 1.846
A.V. Singh et al.2568.787 and 10.864 min, respectively. There was no interference
i.e. peaks observed around the retention time of lamivudine
and IS. The method was found to be linear (R2¼0.998) within
the analytical range of 25.54–2040.75 ng/mL. A maximum
recovery of drug from plasma was resulted using acetonitrile
as extracting solvent in comparisons to other organic solvents.The results obtained proved that the RP-HPLC method
development was accurate and reproducible and the drug
was stable in rabbit plasma. In summary, the optimized
chromatographic estimation of lamivudine with good resolu-
tion can be used for evaluating the bioavailability and also
applied to routine therapeutic monitoring of the lamivudine.Acknowledgement
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